Evidence map›Paper›PMID 34663880›Full record

ReviewOncogene2021

Unravelling roles of error-prone DNA polymerases in shaping cancer genomes.

Cyrus Vaziri, Igor B Rogozin, Qisheng Gu, Di Wu, Tovah A Day

Open access · hybridAbstract readReview
In one paragraph

Review in Oncogene, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 32 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. 8-Oxoadenine: A «New» Player of the Oxidative Stress in Mammals?International journal of molecular sciences · 2024
    Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Cyrus VaziriDepartment of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, 614 Brinkhous-Bullitt Building, Chapel Hill, NC, 27599, USA.
Igor B RogozinNational Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD, 20894, USA.
Qisheng GuDepartment of Biostatistics, University of North Carolina at Chapel Hill, 135 Dauer Drive, 3101 McGavran-Greenberg Hall, Chapel Hill, NC, 27599, USA.ORCID http://orcid.org/0000-0001-7294-042X
Di WuDepartment of Biostatistics, University of North Carolina at Chapel Hill, 135 Dauer Drive, 3101 McGavran-Greenberg Hall, Chapel Hill, NC, 27599, USA.
Tovah A DayDepartment of Biology, Northeastern University, Boston, MA, 02115, USA. t.day@northeastern.edu.ORCID http://orcid.org/0000-0003-3894-1407
University of North Carolina at Chapel Hill · USNational Institutes of Health · USNortheastern University · US

Funding

UNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Hazel B Nichols · 2001 to 2026
$36.3M
Defining Mechanisms of Pathological Trans-Lesion Synthesis During CarcinogenesisR01CA215347 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI VAZIRI, CYRUS, WILLIAMS, SCOTT E · 2018 to 2022
$2.6M
Pathological Reprogramming of DNA Damage Signaling in Neoplastic CellsR01ES029079 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PEARCE, KENNETH HUGH, VAZIRI, CYRUS · 2019 to 2023
$2.3M
Establishing MAGE-A4/RAD18 as a novel cancer-specific chemotherapeutic targetR01CA229530 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI PEARCE, KENNETH HUGH, VAZIRI, CYRUS · 2019 to 2023
$2.0M
The Role of PARP3 in Telomere RegulationK01AG056554 · NIA · NORTHEASTERN UNIVERSITY · PI DAY, TOVAH · 2018 to 2022
$617k
NCI NIH HHS R01 CA215347NCI NIH HHS R01 CA229530NIA NIH HHS K01 AG056554NIEHS NIH HHS P30 ES010126NIEHS NIH HHS R01 ES029079
6 · The paper itself

Abstract

Mutagenesis is a key hallmark and enabling characteristic of cancer cells, yet the diverse underlying mutagenic mechanisms that shape cancer genomes are not understood. This review will consider the emerging challenge of determining how DNA damage response pathways-both tolerance and repair-act upon specific forms of DNA damage to generate mutations characteristic of tumors. DNA polymerases are typically the ultimate mutagenic effectors of DNA repair pathways. Therefore, understanding the contributions of DNA polymerases is critical to develop a more comprehensive picture of mutagenic mechanisms in tumors. Selection of an appropriate DNA polymerase-whether error-free or error-prone-for a particular DNA template is critical to the maintenance of genome stability. We review different modes of DNA polymerase dysregulation including mutation, polymorphism, and over-expression of the polymerases themselves or their associated activators. Based upon recent findings connecting DNA polymerases with specific mechanisms of mutagenesis, we propose that compensation for DNA repair defects by error-prone polymerases may be a general paradigm molding the mutational landscape of cancer cells. Notably, we demonstrate that correlation of error-prone polymerase expression with mutation burden in a subset of patient tumors from The Cancer Genome Atlas can identify mechanistic hypotheses for further testing. We contrast experimental approaches from broad, genome-wide strategies to approaches with a narrower focus on a few hundred base pairs of DNA. In addition, we consider recent developments in computational annotation of patient tumor data to identify patterns of mutagenesis. Finally, we discuss the innovations and future experiments that will develop a more comprehensive portrait of mutagenic mechanisms in human tumors.

Indexed as

DNA DamageDNA RepairGenome, HumanGenomic InstabilityMutationDNA-Directed DNA PolymeraseHumansNeoplasmsDNA-Directed DNA Polymerase

Identifiers

PMID34663880
PMCPMC8639439
OpenAlexW3206847514

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.